Oncology Letters, Journal Year: 2024, Volume and Issue: 28(6)

Published: Oct. 14, 2024

Cholangiocarcinoma (CCA) is a malignant tumor that arises within the biliary system, which exhibits progressively increasing incidence and poor patient prognosis. A thorough understanding of molecular pathogenesis drives progression CCA essential for development effective target therapeutic approaches. Ferroptosis driven by excessive iron accumulation catalysis, lipid peroxidation failure antioxidant defense systems. Key targets metabolism, metabolism systems involve molecules such as transferrin receptor, ACSL4 GPX4, respectively. Inhibitors ferroptosis include ferrostatin-1, liproxstatin-1, vitamin E coenzyme Q10. By contrast, compounds erastin, RSL3 FIN56 have been identified inducers ferroptosis. serves notable role in onset CCA. cells exhibit high sensitivity to aberrant these increases oxidative stress accumulation. The induction markedly reduces ability proliferate migrate. Certain agonists, cause peroxide build up GPX4 inhibition induce cells. Current serological markers, CA-199, low specificity difficulties diagnosis However, novel techniques, non-invasive liquid biopsy assays markers double-cortin-like kinase 1, could improve diagnostic accuracy. primarily treated with surgery chemotherapy. close association between mechanisms related regulatory pathways has demonstrated. Therefore, it be suggested multi-targeted approaches, inducers, chelating agents modulators YL-939, may treatment efficacy. Iron death-related genes, are highly expressed associated prognosis patients represent potential prognostic present review focused on p53 ACSL4, process targeted medications combination PDT peroxidation, Xc

Language: Английский